ArticleMicrobiology (Reading, England)2005
Loss of topoisomerase I function affects the RpoS-dependent and GAD systems of acid resistance in Escherichia coli.
Article in Microbiology (Reading, England), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- An integrated proteo-transcriptomics approach reveals novel drug targets against multidrug resistantFrontiers in microbiology · 2025Article
- Bacterial Topoisomerase I Growth Complementation Assay.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Biochemical Basis ofInternational journal of molecular sciences · 2018Article
- Deacetylation of topoisomerase I is an important physiological function of E. coli CobB.Nucleic acids research · 2017Article
- Topoisomerase I function during Escherichia coli response to antibiotics and stress enhances cell killing from stabilization of its cleavage complex.The Journal of antimicrobial chemotherapy · 2011Article
- ATP requirement for acidic resistance in Escherichia coli.Journal of bacteriology · 2011Article
- Bacterial topoisomerase I as a target for discovery of antibacterial compounds.Nucleic acids research · 2009Review
- SOS induction by stabilized topoisomerase IA cleavage complex occurs via the RecBCD pathway.Journal of bacteriology · 2008Article
- Bacterial cell killing mediated by topoisomerase I DNA cleavage activity.The Journal of biological chemistry · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Acid resistance (AR) in Escherichia coli is important for its survival in the human gastrointestinal tract and involves three systems. The first AR system is dependent on the sigma factor RpoS. The second system (the GAD system) requires the glutamate decarboxylase isoforms encoded by the gadA and gadB genes. The third system (the ARG system) requires the arginine decarboxylase encoded by adiA. Loss of topoisomerase I function from topA deletion or Tn10 insertion mutations lowered the resistance to killing by pH 2 or 2.5 treatment by 10-fold to >100-fold. The RpoS and GAD systems were both affected by the topA mutation, but the ARG system of AR was not affected. Northern blot analysis showed that induction of gadA and gadB transcription in stationary phase and at pH 5.5 was decreased in the topA mutant. Western blot analysis showed that the topA mutation did not affect accumulation of RpoS, GadX or GadW proteins. Topoisomerase I might have a direct influence on the transcription of AR genes. This influence does not involve R-loop formation as the overexpression of RNase H did not alleviate the decrease of AR caused by the topA mutation. The effect of the topA mutation could be suppressed by an hns mutation, so topoisomerase I might be required to counteract the effect of H-NS protein on gene expression, in addition to its influence on RpoS-dependent transcription.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.